Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02939287 · ClinicalTrials.gov registry record · Phase 3
Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan
A Phase 3 study, sponsored by Rush University Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 52
- Enrollment target
NCT02939287 is a Phase 3 study that has completed, run by Rush University Medical Center. The registered enrollment target is 52 participants.
The verdict
NCT02939287, a Phase 3 study, has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to help answer the following research question: * Whether administration of an aprepitant containing regimen, an olanzapine containing regimen or regimen containing both will prevent nausea and vomiting better for patients undergoing an autologous stem cell transplant with melphalan chemotherapy. Both of these medications are approved by the United States Food and Drug Administration (FDA) for nausea and vomiting. * Participants will be randomly assigned to one of the 3 treatment groups: * Arm A: aprepitant containing anti-emetic therapy * Arm B: olanzapine containing anti-emetic therapy * Arm C: Aprepitant plus olanzapine containing anti-emetic therapy
Interventions
- DRUG o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1
- DRUG Olanzapine10 mg orally daily on Days -1,0,+1 and +2
- DRUG Aprepitant plus Olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2017-09-23 |
| Est. Completion | 2022-12-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02939287
The ClinicalTrials.gov registry entry for NCT02939287 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1 is the first listed.
NCT02939287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02939287 about?
NCT02939287 is a clinical study titled "Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan". The purpose of this study is to help answer the following research question: * Whether administration of an aprepitant containing regimen, an olanzapine containing regimen or regimen containing both will prevent nausea and vomiting better for patients undergoing an autologous stem cell transplant w...
What is the current status of trial NCT02939287?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 52 participants. The study started on 2017-09-23. Estimated completion is 2022-12-01.
What interventions are being tested in trial NCT02939287?
The interventions under investigation include: o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1 (DRUG), Olanzapine10 mg orally daily on Days -1,0,+1 and +2 (DRUG), Aprepitant plus Olanzapine (DRUG).
Who is sponsoring clinical trial NCT02939287?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.